New research suggests that inhibiting platelet-derived growth factor (PDGF), which regulates cell growth and division, could help overcome resistance to anti–vascular endothelial growth factor treatment in glioblastoma multiforme.
The anti—vascular endothelial growth factor (anti-VEGF) agent bevacizumab (Avastin), for which a biosimilar (Mvasi) has been approved in the United States, is used to treat a variety of malignancies, including the highly vascularized malignancy glioblastoma.
Glioblastoma cells secrete VEGF, which induces the formation of a dysfunctional vascular system in the tumor, and while ongoing treatment with bevacizumab leads to regression of tumor vasculature, the benefits of bevacizumab in grade IV glioma, or glioblastoma multiforme (GBM), have been small. The slight nature of these benefits may be due to insufficient eradication and inhibition of tumor-associated endothelial cells. Now, new research suggests that inhibiting platelet-derived growth factor (PDGF), which regulates cell growth and division, could help overcome resistance to anti-VEGF therapy in GBM.
Recent clinical studies have shown greater therapeutic efficacy by dual antagonism of PDGF and VEGF in treating age-related macular degeneration, and a research team led by Yi Fan, MD, PhD, investigated whether such a strategy in treating glioblastoma might yield similarly improved benefits.
Click to read more about treating glioblastoma with bevacizumab.
The researchers analyzed specimens and found that VEGF receptor expression was reduced in tumor-derived endothelial cells in both human and mouse GBM endothelial cells. Furthermore, they found that PDGF mediates endothelial-mesenchymal transformation to induce resistance to anti-angiogenic treatment by downregulating expression of VEGF receptor 2 (VEGFR2).
In a mouse model, endothelial cell-specific deletion of PDGF receptor beta was able to sensitize VEGF blockade treatment, and the anti-VEGF agent was then able to efficiently eradicate endothelial cells, leading to abrogated tumor growth and improved survival (+35 days) in GBM-bearing mice.
“Pharmacological inhibition or genetic ablation of PDGF signaling robustly sensitizes anti-VEGF/VEGFR2 treatment in GBM. As such, combination of vascular de-transformation with conventional anti-angiogenic therapy may offer exciting opportunities to treat malignant cancer,” the researchers concluded.
Reference
Liu T, Ma W, Xu H, et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nature Communications. 2018;9:3439. doi: 10.1038/s41467-018-05982-z.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.